WO2022054629A1 - Agent for improving and maintaining oral flora, and agent for removing dental plaque/teeth plaque and preventing tartar formation - Google Patents

Agent for improving and maintaining oral flora, and agent for removing dental plaque/teeth plaque and preventing tartar formation Download PDF

Info

Publication number
WO2022054629A1
WO2022054629A1 PCT/JP2021/031820 JP2021031820W WO2022054629A1 WO 2022054629 A1 WO2022054629 A1 WO 2022054629A1 JP 2021031820 W JP2021031820 W JP 2021031820W WO 2022054629 A1 WO2022054629 A1 WO 2022054629A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
bacteria
gram
biofilm
flora
Prior art date
Application number
PCT/JP2021/031820
Other languages
French (fr)
Japanese (ja)
Inventor
武司 片岡
壮介 小川
知樹 小林
邦義 清水
Original Assignee
株式会社アカシアの樹
国立大学法人九州大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社アカシアの樹, 国立大学法人九州大学 filed Critical 株式会社アカシアの樹
Publication of WO2022054629A1 publication Critical patent/WO2022054629A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • the present invention relates to an oral flora improving / maintaining agent for improving the disorder of the oral flora (bacterial flora) or preventing and maintaining the disorder.
  • Periodontal disease which is one of the oral diseases, is a disease that occurs in the periodontal tissue consisting of four tissues: soft gingiva, root membrane and hard tissue cement, and alveolar bone. Announced by the Ministry of Health, Labor and Welfare (FY2017) ), The total number of patients with "gingival inflammation and periodontal disease” is said to be 3,983,000. There are 300 to 400 types of bacteria in the oral cavity, but when the periodontal disease bacteria contained in them grow abnormally in the gingival sulcus (the boundary between the teeth and gums), a periodontal pocket is formed and the attachment part is the tooth. It peels off the surface, followed by gingival swelling, causing destruction of the alveolar bone.
  • oral diseases such as periodontal disease were thought to be caused by specific pathogens, so antibacterial agents targeting specific pathogens are mainly studied in research aimed at preventing or improving oral diseases.
  • antibacterial agents targeting specific pathogens are mainly studied in research aimed at preventing or improving oral diseases.
  • Patent Document 1 describes an oral composition containing a polyphenol-containing natural product extract and lysine as active ingredients and exhibiting an antibacterial effect against pathogenic bacteria of periodontal disease (particularly Porphyromonas gingivalis). Has been done.
  • Periodontal disease has been considered to be a mixed infection caused by several types of periodontal disease bacteria.
  • periodontal disease is not caused by a single pathogen, but is a disease in which the pathogenicity of biofilm increases as a result of the interaction of various bacterial species including indigenous bacteria, that is, the oral cavity. It has come to be regarded as a disease caused by the disorder of flora (bacterial flora) (Dysbiosis).
  • Oral flora refers to a community of 300 to 400 types of bacteria existing in the oral cavity, and its condition (quality and balance of bacteria, etc.) affects not only the oral cavity but also the health of the whole body.
  • Bacteria that make up the oral flora are roughly composed of three types, good bacteria, bad bacteria, and opportunistic bacteria, and they are fighting for power with each other. The higher the proportion of good bacteria, the healthier it is, and the more bad bacteria it has, the more likely it is that health problems will occur.
  • Optimum bacteria are the bacteria with the highest proportion, but they are harmless when the flora is balanced, but when the number of bad bacteria increases, they become active in the bad bacteria.
  • biofilms In a healthy oral cavity, about 75% of biofilms are indigenous bacteria (gram-positive aerobic bacilli) and are not pathogenic to periodontal disease. However, long-term presence of biofilm in the oral cavity causes gram-negative bacteria such as Fusobacterium, Porphyromonas, Treponema, Prevotella, and Aggregatibacter to grow in the biofilm, with gram-negative anaerobic bacilli occupying about 75% of the oral cavity. As a result, the balance of the oral flora is lost, and diseases and troubles such as periodontal disease and bad breath occur.
  • the condition of the oral flora does not merely affect the health condition of the oral cavity, but also affects the intestinal flora.
  • the intestine is a place that absorbs nutrients and is an important organ that controls 70% of immunity, and intestinal bacteria are greatly involved in these functions. Not only that, it is becoming clear that the products produced by intestinal bacteria affect various organs of the body and even the brain. Deterioration of intestinal flora can be caused by various diseases such as colon cancer, breast cancer and diabetes, obesity, dementia, allergic diseases such as hay fever and atopic dermatitis, autoimmune diseases, and depression. Involved in mental illness.
  • the oral cavity and intestines are separated, they are connected by a tube and affect each other. That is, when the oral flora is predominantly bad bacteria and P. gingivalis increases and flows in large quantities from the mouth to the gastrointestinal tract, most of it is sterilized in the stomach, but some P. gingivalis survive and intestine. It has been reported that the inner flora is out of balance. On the contrary, when the environment of the intestinal flora deteriorates and the number of bad bacteria in the intestine increases, the mucosal barrier function of the intestine that prevents the invasion of harmful substances decreases, and the intestinal bacteria invade the intestinal cells and become inflamed.
  • the present invention particularly suppresses the growth of gram-negative bacteria by reducing the formation rate of the biofilm and releasing the fungi constituting the biofilm from the biofilm.
  • the oral flora can be kept in a good balance.
  • an oral flora improving / maintaining agent containing an acacia bark extract as an active ingredient is provided.
  • the second invention is described in the first invention, which promotes the withdrawal of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm (plaque, plaque).
  • the oral biofilm plaque, plaque.
  • the oral cavity according to the first invention which suppresses the formation of an oral biofilm (plaque, plaque) of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient.
  • an inner flora improving / maintaining agent Provides an inner flora improving / maintaining agent.
  • the gram-negative bacterium and / and the gram-positive bacterium is a second invention or a second invention containing at least two or more of Streptococcus gordonii, Streptococcus mitis, Fusobacterium nucleatum, P. gingivalis, Treponema spp, and Tannerella forsythia.
  • the oral flora improving / maintaining agent according to the third invention is provided.
  • the food and drink containing the oral flora improving / maintaining agent according to any one of the first to fourth inventions is provided.
  • an oral cleansing agent containing the oral flora improving / maintaining agent according to any one of the first invention to the second invention is provided.
  • a dentifrice containing the oral flora improving / maintaining agent according to any one of the first invention to the second invention is provided.
  • the eighth invention provides a plaque / plaque removal agent and a tartar formation preventive agent containing an acacia bark extract as an active ingredient.
  • the ninth invention is the removal of plaque / tartar according to the eighth invention, which promotes the withdrawal of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm. And an agent for preventing tartar formation.
  • the tenth invention includes the removal of plaque / tartar according to the eighth invention, which suppresses the formation of an oral biofilm of Gram-negative bacteria and / and Gram-positive bacteria containing an acacia bark extract as an active ingredient. To provide a tartar formation preventive agent.
  • the gram-negative bacteria and / and the gram-positive bacteria include at least two or more of S. gordonii, S. mitis, F. nucleatum, P. gingivalis, Treponema spp, and T. forsythia.
  • the plaque / plaque removal and anti-stone formation preventive agent according to the ninth invention or the tenth invention are provided.
  • the food and drink containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to ninth inventions is provided.
  • the oral cleansing agent containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to ninth inventions is provided.
  • the dentifrice containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to eleventh inventions is provided.
  • the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to eleventh inventions is used to remove plaque / plaque and prevent tartar formation.
  • an oral flora improving / maintaining method for improving / maintaining an oral flora by using the oral flora improving / maintaining agent according to any one of the first to fourth inventions. offer.
  • the present invention provides an oral flora improving / maintaining agent for improving the disorder of the oral flora or preventing and maintaining the disorder, and also provides a plaque / plaque removal and tartar formation preventive agent. be able to.
  • This embodiment is an oral flora improving / maintaining agent containing an acacia bark extract as an active ingredient. Further, it is a food or drink, an oral cleanser and a dentifrice containing the oral flora improving / maintaining agent. In addition, the oral flora improving / maintaining agent is intended to suppress or decompose the formation of an oral biofilm.
  • Acacia means a tree belonging to the genus Acacia of the leguminous family. Examples of acacia include Acacia mernsii De Wild., Acacia mangium Wild., Acacia dealbata Link, Acacia decurrens Wild., Acacia pycnantha, and the like. Although not particularly limited, the acacia is preferably Acacia mearnsii De Wild. Or Acacia mangium Wild., And more preferably Acacia mearnsii De Wild.
  • This embodiment uses an acacia bark extract.
  • the tree trunk structure is "outer bark-cork forming layer-inner bark-vascular cambium-tree part" from the outside, and generally “outer bark-cork forming layer-inner bark” is used as the bark. I'm calling.
  • the bark in this embodiment is also referred to as “outer bark-cork cambium-inner bark”.
  • Bark extract refers to a substance eluted from the bark with water or an organic solvent.
  • the water is preferably hot water.
  • the organic solvent is preferably an alcohol, more preferably an alcohol having 1 to 4 carbon atoms, and particularly preferably ethanol.
  • the extraction solvent one kind of solvent may be used alone, or two or more kinds of solvents may be used in combination. Further, the bark may be crushed and then extracted, or the bark may be crushed and dried before extraction.
  • proanthocyanidins in the bark extract of Acacia mearnsii are obtained by polymerizing 5-deoxyflavan-3-ols such as robinetinidol and fisetinidol and flavan-3-ols such as catechin and galocatechin (see Reference 1.).
  • the oral flora improving / maintaining agent of the present embodiment has an action of promoting the withdrawal of gram-negative bacteria and / and gram-positive bacteria from the oral biofilm. Further, the oral flora improving / maintaining agent of the present embodiment has an action of suppressing the formation of an oral biofilm of Gram-negative bacteria and / and Gram-positive bacteria.
  • Gram-negative bacteria are bacteria that do not stain purple by the Gram stain method.
  • Gram-negative bacteria include P. gingivalis, Treponema spp, and T. forsythia, and these Gram-negative bacteria are classified into the category with the highest pathogenicity of periodontal disease. It has been reported that T. forsythia aggregates F. nucleatum and T. forsythia, suggesting that preventing F. nucleatum from adhering to the tooth surface makes it difficult for T. forsythia to adhere.
  • Actinobacillus actinomycetemcomitans, Prevotella intermediate, Prevotella denticola, and Prevotella loescheii are also causative bacteria of periodontal disease.
  • F. nucleatum is the causative agent of periodontal disease and plays a central role in the formation of oral biofilm.
  • Prevotella nigrescens is the causative agent of periodontal disease, and it has been pointed out that it is particularly involved in adolescent gingival inflammation and gestational gingival inflammation. It is also known as a cause of chronic persistent inflammation in periodontal disease. It has also been reported that it co-aggregates with F. nucleatum.
  • Capnocytophaga gingivalis As early colony-forming bacteria of oral biofilm, Capnocytophaga gingivalis, Capnocytophaga ochracea, Capnocytophaga spumblea, Eikenella corrodens, Veillonella atypica, Haemophilus parainfluenzae, Campylobacter rectus, Peptostreptococcus micros, Campylobacter There are parvula and so on.
  • Gram-negative bacteria have LPS (lipopolysaccharide) and are not easily released from the cell wall, but are released by thawing and destroying cells when the bacteria die, which acts on animal cells and the like. It is toxic by doing so. ⁇ Gram-positive bacteria>
  • Gram-positive bacteria are bacteria that stain purple by the Gram stain method.
  • Eubacterium spp is the causative bacterium of periodontal disease, and Eubacterium nodatum is said to be the causative bacterium.
  • S. gordonii and S. mitis are classified as early adherent bacteria of biofilm, and it is said that 60 to 90% of the initial colonization is in the genus Streptococcus.
  • the oral biofilm is a white and sticky film in which bacteria grow on the surface of the teeth and the residue of food is sometimes called plaque or plaque.
  • An oral biofilm is a film in which various types of bacteria gather and begin to have a relationship with each other over time, compensating for each other's weaknesses and forming a film. When this oral biofilm is formed, various bacteria that have propagated on the teeth are protected by the cover of the oral biofilm, and the bactericidal power of saliva becomes less effective, leading to the progression of tooth decay and periodontal disease. I will go.
  • the present invention promotes the decomposition of the biofilm in the oral cavity, it inhibits the biofilm from continuing to grow or exist for a long time in the oral cavity, and as a result, the development of the relationship between the bacteria in the biofilm. Inhibits. Inhibition of the development of this relationship results in suppression of the growth of bad bacteria in the biofilm and contributes to maintaining the health of the oral flora.
  • Tartar is a plaque that adheres to the teeth and reacts with calcium and phosphoric acid contained in saliva to calcify, becoming hard like stones and sticking to the surface of the teeth. Tartar is a collection of dead bacteria and does not itself cause periodontal disease like the oral biofilm. The surface of the tartar is uneven, so the oral biofilm tends to adhere. Therefore, it results in further inflammation of the gums.
  • Biofilms formed by bacteria that propagate in the oral cavity are found in halitosis (Reference 5. Koji Shibuya, Study on the components and origin of physiological halitosis, Oral Hygiene Journal, J. Dent. Hlth, 51: 778? 792, 2001, Reference 6). . J. Washio, et al. (2005) Hydrogen sulfide-producinng bacteria in tongue biofilm and their relationship with oral malodour. J. Med. Microbiol., 54, 889-895.), Oral flora imbalance, oral cavity Unsanitary conditions in the mouth, periodontal disease (Refer to 7.
  • FIG. 1 is a diagram showing a formation model of an intraoral biofilm.
  • the process of forming the intraoral biofilm is as follows. First, proteins in saliva adhere to the surface of teeth and form a film called pellicle. Subsequently, initial adhering bacteria such as S. gordonii and S. mitis adhere to the surface of the solid layer to form colonies on the pellicle. Next, the mediator F. nucleatum adheres to the flora, and then P. gingivalis, T. denticola, P. intermedia, A. actinomycetemcomitans, which are pathogens that are the main cause of periodontal disease as late adherent bacteria, are bacteria. The biofilm is formed in three stages: attachment to the flora.
  • Gram-positive bacteria S. gordonii Gram-positive bacteria S. mitis, etc., which are early adherent bacteria, and Gram-negative bacteria F. nucleatum, which are mediators, form biofilms and cause various oral problems.
  • S. gordonii is not only involved in the formation of biofilm in the oral cavity and the subsequent onset of dental caries and gingival inflammation, but is also attracting attention in the fields of dentistry and medicine as the causative agent of infective endocarditis. (Refer to Reference 12. Yukihiro Takahashi et al., Adhesin of Oral Streptococcus pyogenes, Journal of Japanese Bacteriology, 62 (2), 283-293, 2013.).
  • S. gordonii is said to play an important role as an adhesion factor when P. gingivalis becomes a constituent bacterium of dental plaque. Furthermore, it directly destroys periodontal tissue and stimulates immune cells such as macrophages in the periodontal tissue to produce mediators such as inflammatory cytokines, causing damage to the tissue and periodontitis-related cells. It has been shown that it may be involved in periodontitis by indirect mechanisms such as colonization of the lesion and influence of proliferation (Reference 13. Shihoko Tajika et al., Oral cavity of healthy adults and patients with periodontitis. For the distribution of Lenza bulbs, see Iwa Medical University Dental Journal, 21, 66-77, 1996.). S. mitis produces a substance that induces the production of inflammatory cytokines outside the cells, suggesting its potential as a causative agent of various inflammatory diseases.
  • F. nucleatum In F. nucleatum, it is known as a high-producing bacterium of methyl mercaptan (CH 3 SH), which is an odorous substance that causes halitosis, and it is the main cause of halitosis (Reference 5., Reference 14. Miki Matsui et al.) , The condition of gingiva and the involvement of bacteria in halitosis and tongue moss on halitosis in young people without periodontitis. ⁇ Halitosis>
  • the odorous substances that cause halitosis are hydrogen sulfide (H 2 S) and methyl mercaptan (CH 3 SH) produced by bacteria in the oral cavity using amino acids based on proteins present in the oral cavity as substrates.
  • H 2 S hydrogen sulfide
  • CH 3 SH methyl mercaptan
  • methyl mercaptan is always present at a high concentration relative to the cognitive threshold, and the sensory evaluation value (discomfort) is high or low in exhaled breath and mouth with an unpleasant odor. It has been confirmed that this is the main component of the unpleasant odor.
  • Methyl mercaptan has been found to have high production capacity in periodontal disease-related bacteria Porphyromonas and Fusobacterium (see References 5 and 6).
  • F. nucleatum is a long linear gram-negative anaerobic bacterium that is present in large volume ratios in oral biofilms and the like. It is resident in the human oral cavity and is also called a spindle bacterium because both ends of the bacterium are sharp and the central part is slightly thick.
  • F. nucleatum is one of the periodontopathogenic bacteria that plays a central role in the formation of oral biofilms and forms an oral biofilm by co-aggregating with other bacteria. (See Ref. 9, Ref. 10, and Ref. 11.). In addition, it produces butyric acid, which has no sugar resolution and causes bad odor (halitosis). (See Reference 5.). ⁇ Unbalanced oral flora>
  • biofilms In a healthy oral cavity, about 75% of biofilms are indigenous bacteria (gram-positive aerobic bacilli) and are not pathogenic for periodontal disease. On the other hand, in the periodontal pocket of adult periodontitis, gram-negative bacteria such as Fusobacterium, Porphyromonas, Treponema, Prevotella, and Aggregatibacter grow in the biofilm, and gram-negative anaerobic bacilli occupy about 75% of the oral cavity. And the balance of the oral flora is lost. ⁇ Candidiasis>
  • Pneumonia can occur when oral bacteria accidentally enter the lungs through the trachea and spread inflammation. It begins with symptoms such as frequent eating, taking longer than before, and difficulty breathing. Particular attention should be paid to elderly people whose swallowing ability is weakened and patients whose swallowing ability does not function well due to cerebrovascular disease or muscle disease. In severe cases, it can be life-threatening. ⁇ Infective endocarditis>
  • oral flora such as sepsis, myocarditis, arteriosclerosis, diabetes, dermatitis, nephritis, rheumatoid arthritis, and osteoporosis is involved. ⁇ Unsanitary in the oral cavity>
  • F. nucleatum is a long linear gram-negative anaerobic bacterium. It occupies a large volume in the oral biofilm. It is resident in the human oral cavity and has a spindle shape. This bacterium is the central bacterium for the formation of oral biofilm, and forms an oral biofilm by aggregating with other bacteria. ⁇ Periodontal disease>
  • P. gingivalis a gram-negative obligate anaerobic bacterium that is a periodontal disease bacterium, is a pathogenic bacterium that is regarded as important in the onset and progression of periodontitis, and produces a strong protease on the surface of the bacterium and outside the bacterium. It is thought to produce various conditions related to periodontal disease (see Reference 7.).
  • P. gingivalis is known to adhere to the oral biofilm, and it is considered important to control the oral biofilm to which P. gingivalis adheres in order to prevent periodontal disease.
  • P. gingivalis produces pathogenic factors such as internal toxins (LPS), proteases, fibrous hair, and butyric acid, which penetrates into the resorption of gingiva and alveolar bone and enters the tissue gap, and is involved in periodontal tissue destruction. It is thought to be closely related to disease-induced systemic diseases. In addition, there are pathogenic bacteria that are regarded as important in the onset and progression of periodontal disease, and A. actinomycetemcomitans, which is said to be closely related to invasive periodontitis, is extrabacterial. It has vesicles, and toxins such as internal toxins and leukotoxins are present, which induces cell apoptosis, and P. intermedi is associated with invasive periodontitis for adolescent gingitis and gestational gingitis. It has been pointed out that they are involved. ⁇ Mechanism of inflammation caused by P. gingivalis>
  • Toxins such as LPS, gingipain, and leukotoxin produced by the bacteria forming the biofilm cause an inflammatory reaction locally in the periodontal tissue.
  • various cytokines and enzymes such as IL-1 ⁇ and TNF- ⁇ destroy periodontal tissue. If the periodontal tissue is continuously stimulated chronically, the host cells cause a continuous or excessive immune reaction in the periodontal tissue, and the periodontal tissue is repeatedly destroyed.
  • periodontal disease is not limited to local inflammation in the oral cavity, but is caused by inflammatory factors such as inflammatory cytokines (IL-1 ⁇ , 6, 8, TNF- ⁇ , etc.) produced by the bacteria themselves and immune reactions.
  • IL-1 ⁇ , 6, 8, TNF- ⁇ , etc. inflammatory cytokines
  • the spread of inflammation to the whole body through periodontal pathogens and their immune reactions has been attracting attention as a link between periodontal disease and systemic disease (see Reference 8.).
  • a pericle On the tooth surface, what is called a pericle to which proteins and organic substances are bound is formed.
  • an early colonizers that attaches to the protein receptor of the pellicle and begins to form a colony.
  • S. mitis, S. gordonii, etc. are established as an early colonization group among indigenous oral bacteria.
  • the pellicle is hidden and disappears.
  • the bacterial group having adhesin against the surface protein on the bacterial surface of the early colonization group grows as a receptor. Then, the bacteria settle and proliferate in a coherent manner due to the relationship between the receptor and adhesin. In this way, colonies of late colonization bacteria are completed.
  • the spindle fungus F. nucleatum plays a central role in the oral cavity.
  • Brainheart infusion bouillon medium (Nissui Pharmaceutical Co., Ltd.) with S. gordonii (initial adherent bacteria), S. mitis (initial adherent bacteria), F. nucleatum subsp. Nucleatum (JCM No. 8532) 6 to 7 respectively. Precultured for days at 37 ° C. under anaerobic conditions (Aneropack Kenki, Mitsubishi Gas Chemicals Co., Ltd.). ⁇ Biofilm formation inhibition test>
  • FIG. 2 is a conceptual diagram showing a method of a biofilm formation inhibition test.
  • a 96-well plate was immersed in an acacia bark extract sample for 5 minutes in a clean bench, then the acacia bark extract sample was removed and air-dried for 60 minutes.
  • Acacia bark extraction is performed by inoculating pre-cultured S. gordonii (initial adherent bacteria), S. mitis (initial adherent bacteria), and F. nucleatum subsp. Nucleatum (JCM No. 8532) in 1% each of the medium. 100 ⁇ L was added to each of the 96-well plates coated with the product sample. Then, it was statically cultured for 2 days at 37 ° C.
  • FIG. 3 is a conceptual diagram showing a method of a biofilm removal test.
  • S. gordoni initial adherent bacteria
  • S. mitis initial adherent bacteria
  • F. nucleatum subsp. Nucleatum JCM No. 8532
  • FIG. 4 shows the results of the biofilm formation inhibition test, showing the proportion of biofilm formed on 96-well plates pretreated with acacia bark extract samples.
  • a decrease in the biofilm formation rate was confirmed in the test plots pretreated with the acacia bark extract sample as compared with the control.
  • the acacia bark extract sample 3 mg / mL concentration treatment group it was found that the formation of biofilm was significantly inhibited as compared with the control (water).
  • FIG. 5 is a diagram showing the results of the biofilm removal test, showing the turbidity of the bacteria released by the biofilm formed on the 96-well plate by the treatment of the acacia bark extract sample.
  • the oral flora improving / maintaining agent of the present embodiment can be provided in the form of solid, granular, liquid, gel, powder, paste and the like. Further, by using a known method, it can be provided as a food or drink, an oral cleanser, a dentifrice or the like containing the oral flora improving / maintaining agent.

Abstract

[Problem] The state of an oral flora not only influences the oral health status but also affects an intestinal flora. Deterioration of the intestinal flora leads to various diseases, autoimmune disorders, depression, etc. The balance of the oral flora is disrupted by the formation of an oral biofilm as well as the prolonged presence thereof. Therefore, oral biofilms become a pressing issue. [Solution] An agent for improving and maintaining an oral flora, said agent comprising an acacia bark extract as an active ingredient. This agent lowers the oral biofilm formation rate and releases biofilm-forming bacteria from the biofilm. As a result, the agent inhibits the growth of gram-negative bacteria and removes the gram-negative bacteria together with other bacteria to thereby enable the oral flora to keep a good balance.

Description

口腔内フローラ改善・維持剤、プラーク/歯垢の除去及び歯石形成予防剤Oral flora improving / maintaining agent, plaque / plaque removal and tartar formation preventive agent
 本発明は、口腔内フローラ(細菌叢)の乱れを改善し、あるいは乱れを防止して維持するための口腔内フローラ改善・維持剤に関する。 The present invention relates to an oral flora improving / maintaining agent for improving the disorder of the oral flora (bacterial flora) or preventing and maintaining the disorder.
 口腔内疾患の一つである歯周病は、軟組織の歯肉、歯根膜と硬組織のセメント質、歯槽骨の4つの組織からなる歯周組織に生じる疾患であり、厚生労働省の発表(2017年度)によれば、「歯肉炎及び歯周疾患」の総患者数は、398万3000人といわれている。口腔内には300~400種類の細菌が存在するが、そのなかに含まれる歯周病菌が歯肉溝(歯と歯ぐきの境目)のなかで異常増殖すると歯周ポケットが形成され、付着部が歯面から剥がれ、続いて歯肉がはれ、歯槽骨の破壊を引き起こす。 Periodontal disease, which is one of the oral diseases, is a disease that occurs in the periodontal tissue consisting of four tissues: soft gingiva, root membrane and hard tissue cement, and alveolar bone. Announced by the Ministry of Health, Labor and Welfare (FY2017) ), The total number of patients with "gingival inflammation and periodontal disease" is said to be 3,983,000. There are 300 to 400 types of bacteria in the oral cavity, but when the periodontal disease bacteria contained in them grow abnormally in the gingival sulcus (the boundary between the teeth and gums), a periodontal pocket is formed and the attachment part is the tooth. It peels off the surface, followed by gingival swelling, causing destruction of the alveolar bone.
 従来、歯周病などの口腔内疾患は特定の病原菌に起因すると考えられていたため、口腔内疾患の予防や改善を図る研究においても、特定の病原菌を対象とした抗菌剤などが主に研究されていた。 In the past, oral diseases such as periodontal disease were thought to be caused by specific pathogens, so antibacterial agents targeting specific pathogens are mainly studied in research aimed at preventing or improving oral diseases. Was there.
 例えば、特許文献1には、含ポリフェノール天然物エキス及びリシンを有効成分として、歯周病の病原菌(特にPorphyromonas gingivalis(ポルフィロモナス・ジンジバリス))に対して抗菌作用を示す口腔用組成物について記載されている。 For example, Patent Document 1 describes an oral composition containing a polyphenol-containing natural product extract and lysine as active ingredients and exhibiting an antibacterial effect against pathogenic bacteria of periodontal disease (particularly Porphyromonas gingivalis). Has been done.
特開2019-210252号公報Japanese Unexamined Patent Publication No. 2019-21252
 歯周病は数種の歯周病菌種による混合感染と考えられてきた。しかし、近年、歯周病は単一の病原菌に起因するのではなく、常在菌を含めた多様な細菌種の相互作用の結果によりバイオフィルムの病原性が高まり発症に至る疾患、つまり口腔内フローラ(細菌叢)の乱れ(Dysbiosis)に由来する疾患であると捉えられるようになってきた。 Periodontal disease has been considered to be a mixed infection caused by several types of periodontal disease bacteria. However, in recent years, periodontal disease is not caused by a single pathogen, but is a disease in which the pathogenicity of biofilm increases as a result of the interaction of various bacterial species including indigenous bacteria, that is, the oral cavity. It has come to be regarded as a disease caused by the disorder of flora (bacterial flora) (Dysbiosis).
 口腔内フローラは、口腔内に存在する300~400種の細菌の群集をいい、その状態(細菌の質やバランスなど)が口腔内のみならず全身の健康に影響を及ぼす。口腔内フローラを構成する細菌は、大まかに善玉菌、悪玉菌、日和見菌の3種類からなっており、互いに勢力争いを行っている。善玉菌の割合が高いほど健康で、悪玉菌が多いほど健康上のトラブルが生じやすくなる。日和見菌は最も高い比率を占める細菌だが、フローラのバランスが保たれた状態では無害だが、悪玉菌が増加すると悪玉菌に加勢する。 Oral flora refers to a community of 300 to 400 types of bacteria existing in the oral cavity, and its condition (quality and balance of bacteria, etc.) affects not only the oral cavity but also the health of the whole body. Bacteria that make up the oral flora are roughly composed of three types, good bacteria, bad bacteria, and opportunistic bacteria, and they are fighting for power with each other. The higher the proportion of good bacteria, the healthier it is, and the more bad bacteria it has, the more likely it is that health problems will occur. Optimum bacteria are the bacteria with the highest proportion, but they are harmless when the flora is balanced, but when the number of bad bacteria increases, they become active in the bad bacteria.
 健康な口腔内では、バイオフィルムの約75%が常在菌(グラム陽性好気性球桿菌)であり、歯周病の病原性はない。しかし、口腔内にバイオフィルムが長期に存在するとFusobacterium、Porphyromonas、Treponema、Prevotella、Aggregatibacterなどのグラム陰性菌がバイオフィルム内で増殖し、グラム陰性嫌気性球桿菌が口腔内の約75%を占めるようになり、口腔内フローラのバランスが崩れ、歯周病や口臭などの疾病やトラブルが発生する。 In a healthy oral cavity, about 75% of biofilms are indigenous bacteria (gram-positive aerobic bacilli) and are not pathogenic to periodontal disease. However, long-term presence of biofilm in the oral cavity causes gram-negative bacteria such as Fusobacterium, Porphyromonas, Treponema, Prevotella, and Aggregatibacter to grow in the biofilm, with gram-negative anaerobic bacilli occupying about 75% of the oral cavity. As a result, the balance of the oral flora is lost, and diseases and troubles such as periodontal disease and bad breath occur.
 また、口腔内フローラの状態は、単に口腔内の健康状態を左右するものではなく、腸内フローラにも影響を及ぼす。腸は、栄養素を吸収する場所であり、免疫の7割を司る重要な臓器であり、腸内細菌はこれらの働きに大きく関わっている。またそれだけでなく、腸内細菌が作り出す産生物が体の様々な臓器や脳にまでも影響を与えることがわかってきている。腸内フローラの悪化は様々な疾患、例えば、大腸ガン、乳ガンや糖尿病、肥満、認知症、そして花粉症やアトピー性皮膚炎などのようなアレルギー性疾患、自己免疫疾患のほか、うつ病などの心の病気に関与している。 In addition, the condition of the oral flora does not merely affect the health condition of the oral cavity, but also affects the intestinal flora. The intestine is a place that absorbs nutrients and is an important organ that controls 70% of immunity, and intestinal bacteria are greatly involved in these functions. Not only that, it is becoming clear that the products produced by intestinal bacteria affect various organs of the body and even the brain. Deterioration of intestinal flora can be caused by various diseases such as colon cancer, breast cancer and diabetes, obesity, dementia, allergic diseases such as hay fever and atopic dermatitis, autoimmune diseases, and depression. Involved in mental illness.
 そして、口腔と腸とは離れているとはいえ、管でつながっており互いに影響を与え合う。すなわち、口腔内フローラの状態が悪玉菌優勢で、P. gingivalisが増えて大量に口から消化管の方に流れ込むと、ほとんどは胃で殺菌されるが、一部のP. gingivalisは生き残って腸内フローラのバランスを崩すことが報告されている。また逆に、腸内フローラの環境が悪化し、腸内の悪玉菌が増えた状態になると、有害物質の侵入を防ぐ腸の粘膜バリア機能が低下し、腸内細菌が腸管細胞に侵入し炎症を起こすとともに、体全体の免疫力を低下させ、全身的な炎症を起こしたり、感染症にかかりやすくなる。そのため、歯周病菌が増えやすい環境となり、口腔内フローラの状態も悪くなることが考えられる。 And even though the oral cavity and intestines are separated, they are connected by a tube and affect each other. That is, when the oral flora is predominantly bad bacteria and P. gingivalis increases and flows in large quantities from the mouth to the gastrointestinal tract, most of it is sterilized in the stomach, but some P. gingivalis survive and intestine. It has been reported that the inner flora is out of balance. On the contrary, when the environment of the intestinal flora deteriorates and the number of bad bacteria in the intestine increases, the mucosal barrier function of the intestine that prevents the invasion of harmful substances decreases, and the intestinal bacteria invade the intestinal cells and become inflamed. At the same time, it weakens the immune system of the whole body, causes systemic inflammation, and becomes susceptible to infections. Therefore, it is possible that the environment is such that periodontal disease bacteria are likely to increase, and the condition of the oral flora also deteriorates.
 本発明は、上記の事情を鑑み、とくにバイオフィルムの形成率を低下させたり、バイオフィルムを構成する菌類をバイオフィルムから遊離させたりすることで、結果としてグラム陰性菌の増殖を抑制したり、他の菌と相まってグラム陰性菌を除去することで、口腔内フローラが良好なバランスでいられることを図るものである。 In view of the above circumstances, the present invention particularly suppresses the growth of gram-negative bacteria by reducing the formation rate of the biofilm and releasing the fungi constituting the biofilm from the biofilm. By removing Gram-negative bacteria in combination with other bacteria, the oral flora can be kept in a good balance.
 そこで、上記課題を解決するために、第一の発明として、アカシアの樹皮抽出物を有効成分とする口腔内フローラ改善・維持剤を提供する。 Therefore, in order to solve the above-mentioned problems, as a first invention, an oral flora improving / maintaining agent containing an acacia bark extract as an active ingredient is provided.
 第二の発明としては、アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルム(プラーク、歯垢)からの離脱を促進する第一の発明に記載の口腔内フローラ改善・維持剤を提供する。 The second invention is described in the first invention, which promotes the withdrawal of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm (plaque, plaque). Provides an oral flora improving / maintaining agent.
 第三の発明としては、アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルム(プラーク、歯垢)の形成を抑制する第一の発明に記載の口腔内フローラ改善・維持剤を提供する。 As the third invention, the oral cavity according to the first invention, which suppresses the formation of an oral biofilm (plaque, plaque) of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient. Provides an inner flora improving / maintaining agent.
 第四の発明としては、前記グラム陰性菌又は/及びグラム陽性菌は、Streptococcus gordonii、Streptococcus mitis、Fusobacterium nucleatum、P. gingivalis、Treponema spp、Tannerella forsythiaのうちの少なくとも二以上を含む第二の発明又は第三の発明に記載の口腔内フローラ改善・維持剤を提供する。 As a fourth invention, the gram-negative bacterium and / and the gram-positive bacterium is a second invention or a second invention containing at least two or more of Streptococcus gordonii, Streptococcus mitis, Fusobacterium nucleatum, P. gingivalis, Treponema spp, and Tannerella forsythia. Provided is the oral flora improving / maintaining agent according to the third invention.
 第五の発明としては、第一の発明から第4の発明のいずれか一に記載の口腔内フローラ改善・維持剤を含有した飲食料を提供する。 As the fifth invention, the food and drink containing the oral flora improving / maintaining agent according to any one of the first to fourth inventions is provided.
 第六の発明としては、第一の発明から第二の発明のいずれか一に記載の口腔内フローラ改善・維持剤を含有した口腔洗浄剤を提供する。 As the sixth invention, an oral cleansing agent containing the oral flora improving / maintaining agent according to any one of the first invention to the second invention is provided.
 第七の発明としては、第一の発明から第二の発明のいずれか一に記載の口腔内フローラ改善・維持剤を含有した歯磨剤を提供する。 As the seventh invention, a dentifrice containing the oral flora improving / maintaining agent according to any one of the first invention to the second invention is provided.
 第八の発明としては、アカシアの樹皮抽出物を有効成分とするプラーク/歯垢の除去及び歯石形成予防剤を提供する。 The eighth invention provides a plaque / plaque removal agent and a tartar formation preventive agent containing an acacia bark extract as an active ingredient.
 第九の発明としては、アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムからの離脱を促進する第八の発明に記載のプラーク/歯垢の除去及び歯石形成予防剤を提供する。 The ninth invention is the removal of plaque / tartar according to the eighth invention, which promotes the withdrawal of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm. And an agent for preventing tartar formation.
 第十の発明としては、アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムの形成を抑制する第八の発明に記載のプラーク/歯垢の除去及び歯石形成予防剤を提供する。 The tenth invention includes the removal of plaque / tartar according to the eighth invention, which suppresses the formation of an oral biofilm of Gram-negative bacteria and / and Gram-positive bacteria containing an acacia bark extract as an active ingredient. To provide a tartar formation preventive agent.
 第十一の発明としては、前記グラム陰性菌又は/及びグラム陽性菌は、S. gordonii、S. mitis、F. nucleatum、P. gingivalis、Treponema spp、T. forsythiaのうちの少なくとも二以上を含む第九の発明又は第十の発明に記載のプラーク/歯垢の除去及び歯石形成予防剤を提供する。 In the eleventh invention, the gram-negative bacteria and / and the gram-positive bacteria include at least two or more of S. gordonii, S. mitis, F. nucleatum, P. gingivalis, Treponema spp, and T. forsythia. Provided are the plaque / plaque removal and anti-stone formation preventive agent according to the ninth invention or the tenth invention.
 第十二の発明としては、第八の発明から第九の発明のいずれか一に記載のプラーク/歯垢の除去及び歯石形成予防剤を含有した飲食料を提供する。 As the twelfth invention, the food and drink containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to ninth inventions is provided.
 第十三の発明としては、第八の発明から第九の発明のいずれか一に記載のプラーク/歯垢の除去及び歯石形成予防剤を含有した口腔洗浄剤を提供する。 As the thirteenth invention, the oral cleansing agent containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to ninth inventions is provided.
 第十四の発明としては、第八の発明から第十一の発明のいずれか一に記載のプラーク/歯垢の除去及び歯石形成予防剤を含有した歯磨剤を提供する。 As the fourteenth invention, the dentifrice containing the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to eleventh inventions is provided.
 第十五の発明としては、第八の発明から第十一の発明のいずれか一に記載のプラーク/歯垢の除去及び歯石形成予防剤を用いてプラーク/歯垢の除去及び歯石形成予防するプラーク/歯垢の除去及び歯石形成予防方法を提供する。 As the fifteenth invention, the plaque / plaque removal and tartar formation preventive agent according to any one of the eighth to eleventh inventions is used to remove plaque / plaque and prevent tartar formation. Provided are methods for removing plaque / plaque and preventing tartar formation.
 第十六の発明としては、第一の発明から第四の発明のいずれか一に記載の口腔内フローラ改善・維持剤を用いて口腔内フローラを改善・維持する口腔内フローラ改善・維持方法を提供する。 As the sixteenth invention, an oral flora improving / maintaining method for improving / maintaining an oral flora by using the oral flora improving / maintaining agent according to any one of the first to fourth inventions. offer.
 本発明により、口腔内フローラの乱れを改善し、あるいは乱れを予防して維持するための口腔内フローラ改善・維持剤を提供し、また、プラーク/歯垢の除去及び歯石形成予防剤を提供することができる。 INDUSTRIAL APPLICABILITY The present invention provides an oral flora improving / maintaining agent for improving the disorder of the oral flora or preventing and maintaining the disorder, and also provides a plaque / plaque removal and tartar formation preventive agent. be able to.
口腔内バイオフィルムの形成モデルを示す図The figure which shows the formation model of the intraoral biofilm バイオフィルム形成阻害試験の方法を示す概念図Conceptual diagram showing the method of biofilm formation inhibition test バイオフィルム除去試験の方法を示す概念図Conceptual diagram showing the method of biofilm removal test バイオフィルム形成阻害試験の結果を示す図The figure which shows the result of the biofilm formation inhibition test バイオフィルム除去試験の結果を示す図The figure which shows the result of the biofilm removal test
 以下、本発明の実施の形態について、添付図面を用いて説明する。なお、本発明は、これら実施形態に何ら限定されるべきものではなく、その要旨を逸脱しない範囲において、種々なる態様で実施し得る。
<実施形態1>
<概要>
Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. The present invention should not be limited to these embodiments, and may be implemented in various embodiments without departing from the gist thereof.
<Embodiment 1>
<Overview>
 本実施形態は、アカシアの樹皮抽出物を有効成分とする口腔内フローラ改善・維持剤である。また、この口腔内フローラ改善・維持剤を含有した飲食料、口腔洗浄剤及び歯磨剤である。また、口腔内フローラ改善・維持剤は、口腔内バイオフィルムの形成抑制又は分解を図るものである。
<構成>
This embodiment is an oral flora improving / maintaining agent containing an acacia bark extract as an active ingredient. Further, it is a food or drink, an oral cleanser and a dentifrice containing the oral flora improving / maintaining agent. In addition, the oral flora improving / maintaining agent is intended to suppress or decompose the formation of an oral biofilm.
<Structure>
 「アカシア」は、マメ科アカシア(Acacia)属に属する樹木を意味する。アカシアとしては、例えば、Acacia mearnsii De Wild.、Acacia mangium Willd.、Acacia dealbata Link、Acacia decurrens Willd.、Acacia pycnantha Benth. 等が挙げられる。特に限定するものではないが、アカシアは、好ましくはAcacia mearnsii De Wild.又はAcacia mangium Willd.であり、より好ましくはAcacia mearnsii De Wild.である。 "Acacia" means a tree belonging to the genus Acacia of the leguminous family. Examples of acacia include Acacia mernsii De Wild., Acacia mangium Wild., Acacia dealbata Link, Acacia decurrens Wild., Acacia pycnantha, and the like. Although not particularly limited, the acacia is preferably Acacia mearnsii De Wild. Or Acacia mangium Wild., And more preferably Acacia mearnsii De Wild.
 本実施形態はアカシアの樹皮抽出物を用いる。樹木の樹幹構造は、外側から「外樹皮―コルク形成層―内樹皮―維管束形成層―木部」となっており、一般的には「外樹皮―コルク形成層―内樹皮」を樹皮と呼んでいる。本実施形態における樹皮も同様に「外樹皮―コルク形成層―内樹皮」とする。 This embodiment uses an acacia bark extract. The tree trunk structure is "outer bark-cork forming layer-inner bark-vascular cambium-tree part" from the outside, and generally "outer bark-cork forming layer-inner bark" is used as the bark. I'm calling. Similarly, the bark in this embodiment is also referred to as "outer bark-cork cambium-inner bark".
 樹皮抽出物は、水や有機溶媒により樹皮から溶出させた物質をいう。水は熱水であることが好ましい。有機溶媒は、好ましくはアルコールであり、より好ましくは炭素数1~4のアルコールであり、特に好ましくはエタノールである。抽出溶媒は、1種の溶媒を単独で使用してもよいし、2種以上の溶媒を組み合わせて使用してもよい。また、樹皮を破砕してから抽出したり、破砕と乾燥を行ってから抽出してもよい。 Bark extract refers to a substance eluted from the bark with water or an organic solvent. The water is preferably hot water. The organic solvent is preferably an alcohol, more preferably an alcohol having 1 to 4 carbon atoms, and particularly preferably ethanol. As the extraction solvent, one kind of solvent may be used alone, or two or more kinds of solvents may be used in combination. Further, the bark may be crushed and then extracted, or the bark may be crushed and dried before extraction.
 アカシア樹皮抽出物はそのおよそ4分の3がプロアントシアニジン、およそ4分の1がスクロースなどの糖からなることが知られている。(文献1.Rie Kusano, et al., α-Amylase and Lipase Inhibitory Activity and Structural Characterization of Acacia Bark Proanthocyanidins, J Nat Prod. 2011 Feb 25;74(2):119-28.参照)(文献2.Yosuke Matsuo, et al, Characterization of the α-Amylase Inhibitory Activity of Oligomeric Proanthocyanidins from Acacia mearnsii Bark Extract, Natural product Communications, Vol.11 No.12 1851-1854, 2016参照)。 It is known that about three-quarters of acacia bark extract consists of proanthocyanidins and about one-fourth consists of sugars such as sucrose. (Reference 1. Rie Kusano, et al., Α-Amylase and Lipase Inhibitory Activity and Structural characterization of Acacia Bark Proanthocyanidins, J Nat Prod. 2011 Feb 25; 74 (2): 119-28.) Matsuo, et al, characterization of the α-Amylase Inhibitory Activity of Oligomeric Proanthocyanidins from Acacia learnsii Bark Extract, Natural product Communications, Vol.11 No.12 1851-1854, 2016).
 また、Acacia mearnsiiの樹皮抽出物におけるプロアントシアニジンは、ロビネチニドールやフィセチニドールといった5-デオキシフラバン-3-オールおよびカテキン、ガロカテキンといったフラバン-3-オールが重合してなる(文献1.参照)。 Further, proanthocyanidins in the bark extract of Acacia mearnsii are obtained by polymerizing 5-deoxyflavan-3-ols such as robinetinidol and fisetinidol and flavan-3-ols such as catechin and galocatechin (see Reference 1.).
 本実施形態の口腔内フローラ改善・維持剤は、グラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムからの離脱を促進する作用を有する。また本実施形態の口腔内フローラ改善・維持剤は、グラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムの形成を抑制する作用を有する。 The oral flora improving / maintaining agent of the present embodiment has an action of promoting the withdrawal of gram-negative bacteria and / and gram-positive bacteria from the oral biofilm. Further, the oral flora improving / maintaining agent of the present embodiment has an action of suppressing the formation of an oral biofilm of Gram-negative bacteria and / and Gram-positive bacteria.
 以下に詳述するStreptococcus mutans、 Streptococcus sobrinusのほかに歯周病関連菌群, Pseudomonas aeruginosa などは、バイオフィルムを積極的に形成するために糖から大量のグルカンを合成することが知られている。(文献3.花田、口腔における細菌性バイオフィルムの制御について、老年歯学 第16巻 第3号 2002参照)さらに、スクロースは、高エネルギー結合を有しているために、細菌は加水分解によって粘着性・不溶性のグルカンを作り、バイオフィルムを形成することが知られている。(文献4.花田、バイオフィルムの臨床生物学、J Health Care Dent. 2003; 5: 4-30.参照)スクロースなどの糖は、上述のとおり、バイオフィルムの形成を進めるものであり、形成阻害や離脱を促進するものではない。したがって、アカシア樹皮抽出物の中のプロアントシアニジンが関与成分であると考えられる。
<グラム陰性菌>
In addition to Streptococcus mutans and Streptococcus sobrinus described in detail below, periodontal disease-related fungi, Pseudomonas aeruginosa, etc. are known to synthesize large amounts of glucan from sugar in order to actively form biofilms. (Refer to 3. Hanada, Control of Bacterial Biofilm in Oral Geriatric Dentistry, Vol. 16, No. 3, 2002) Furthermore, because sucrose has a high-energy bond, bacteria become sticky due to hydrolysis. -It is known to make insoluble glucan and form biofilms. (Refer to Reference 4. Hanada, Clinical Biology of Biofilm, J Health Care Dent. 2003; 5: 4-30.) As mentioned above, sugars such as sucrose promote the formation of biofilm and inhibit the formation. It does not promote withdrawal. Therefore, it is considered that proanthocyanidins in the acacia bark extract are involved components.
<Gram-negative bacteria>
 グラム陰性菌は、グラム染色法によって紫色に染まらない菌をいう。グラム陰性菌としては、例えば、P. gingivalis、Treponema spp、T. forsythiaがあり、これらのグラム陰性菌は歯周病の病原性が最も高いカテゴリーに分類される。なお、T. forsythiaは、F. nucleatumとT. forsythiaが凝集するという報告がなされており、F. nucleatumの歯面への付着を防ぐことで、T. forsythiaも付着しにくくなると示唆される。また、Actinobacillus actinomycetemcomitans、Prevotella intermedia、Prevotella denticola、Prevotella loescheiiも歯周病の原因菌である。また、F. nucleatumは、歯周病の原因菌であるとともに口腔内バイオフィルム形成の中心的な役割を担う。Prevotella nigrescensは、歯周病の原因菌であり、特に思春期性歯肉炎や妊娠性歯肉炎への関与が指摘されている。また歯周疾患における慢性持続性炎症の原因としても知られている。またF. nucleatumと共凝集することも報告されている。また、口腔内バイオフィルムの早期コロニー形成菌として、Capnocytophaga gingivalis、Capnocytophaga ochracea、Capnocytophaga sputigena、Eikenella corrodens、Veillonella atypica、Haemophilus parainfluenzae、Campylobacter rectus、Peptostreptococcus micros、Campylobacter gracilis、Campylobacter showae、Fusobacterium polymorphum、Campylobacter concisus 、Veillonella parvulaなどがある。 Gram-negative bacteria are bacteria that do not stain purple by the Gram stain method. Examples of Gram-negative bacteria include P. gingivalis, Treponema spp, and T. forsythia, and these Gram-negative bacteria are classified into the category with the highest pathogenicity of periodontal disease. It has been reported that T. forsythia aggregates F. nucleatum and T. forsythia, suggesting that preventing F. nucleatum from adhering to the tooth surface makes it difficult for T. forsythia to adhere. In addition, Actinobacillus actinomycetemcomitans, Prevotella intermediate, Prevotella denticola, and Prevotella loescheii are also causative bacteria of periodontal disease. In addition, F. nucleatum is the causative agent of periodontal disease and plays a central role in the formation of oral biofilm. Prevotella nigrescens is the causative agent of periodontal disease, and it has been pointed out that it is particularly involved in adolescent gingival inflammation and gestational gingival inflammation. It is also known as a cause of chronic persistent inflammation in periodontal disease. It has also been reported that it co-aggregates with F. nucleatum. In addition, as early colony-forming bacteria of oral biofilm, Capnocytophaga gingivalis, Capnocytophaga ochracea, Capnocytophaga sputigena, Eikenella corrodens, Veillonella atypica, Haemophilus parainfluenzae, Campylobacter rectus, Peptostreptococcus micros, Campylobacter There are parvula and so on.
 グラム陰性菌は、LPS(リポ多糖体)を有し、細胞壁から容易には遊離せず、細菌が死滅したときなどに細胞が融解・破壊されることで遊離し、それが動物細胞などに作用することで毒性を発揮する。
<グラム陽性菌>
Gram-negative bacteria have LPS (lipopolysaccharide) and are not easily released from the cell wall, but are released by thawing and destroying cells when the bacteria die, which acts on animal cells and the like. It is toxic by doing so.
<Gram-positive bacteria>
 グラム陽性菌は、グラム染色法によって紫色に染まる菌をいう。例えば、Eubacterium sppは、歯周病の原因菌であり、特にEubacterium nodatumが原因菌といわれている。また、S. gordoniiとS. mitisは、バイオフィルムの初期付着菌に分類され、初期コロニー形成の6-9割がstreptococcus属だといわれている。また、口腔内バイオフィルムの早期コロニー形成菌として、Actinomyces israelii、Actinomyces naeslundii、Propionibacterium acnes、Selenomonas flueggei、Streptococcus oralis、Streptococcus sanguis、Streptococcus constellatus、Streptococcus intermedius、Actinomyces odontolytiusなどがある。
<口腔内バイオフィルム>
Gram-positive bacteria are bacteria that stain purple by the Gram stain method. For example, Eubacterium spp is the causative bacterium of periodontal disease, and Eubacterium nodatum is said to be the causative bacterium. In addition, S. gordonii and S. mitis are classified as early adherent bacteria of biofilm, and it is said that 60 to 90% of the initial colonization is in the genus Streptococcus. In addition, as early colony-forming bacteria of oral biofilm, there are Actinomyces israelii, Actinomyces naeslundii, Propionibacterium acnes, Selenomonas flueggei, Streptococcus oralis, Streptococcus sanguis, Streptococcus constellatus, Streptococcus intermedius, Actinomyces odontolytius and the like.
<Intraoral biofilm>
 口腔内バイオフィルムとは、食べものの残りカスが歯の表面につき細菌が繁殖したもので、白くねばねばしているものであり、プラークや歯垢と呼ばれることもある。口腔内バイオフィルムは幾種もの菌が集合し、時間の経過とともに関係性を持ち始め、互いの弱点を補いながら、膜(フィルム)を形成したもののことを指す。この口腔内バイオフィルムが形成されると、歯に付いて繁殖した幾種もの菌が口腔内バイオフィルムのカバーにより守られ、唾液による殺菌力が効きにくくなり、虫歯や歯周病を進行させていくことになる。 The oral biofilm is a white and sticky film in which bacteria grow on the surface of the teeth and the residue of food is sometimes called plaque or plaque. An oral biofilm is a film in which various types of bacteria gather and begin to have a relationship with each other over time, compensating for each other's weaknesses and forming a film. When this oral biofilm is formed, various bacteria that have propagated on the teeth are protected by the cover of the oral biofilm, and the bactericidal power of saliva becomes less effective, leading to the progression of tooth decay and periodontal disease. I will go.
 本件発明は、口腔内バイオフィルムの分解を促進するので、口腔内で長時間バイオフィルムが成長し続けたり、存在し続けることを阻害し、結果として、バイオフィルム中の菌どうしの関係性の発展を阻害する。この関係性の発展の阻害は結果としてバイオフィルム中の悪玉菌の増殖を抑え、口腔内フローラの健全性を保つことに貢献する。 Since the present invention promotes the decomposition of the biofilm in the oral cavity, it inhibits the biofilm from continuing to grow or exist for a long time in the oral cavity, and as a result, the development of the relationship between the bacteria in the biofilm. Inhibits. Inhibition of the development of this relationship results in suppression of the growth of bad bacteria in the biofilm and contributes to maintaining the health of the oral flora.
 歯石は、歯に付着したプラークが唾液に含まれるカルシウムやリン酸などと反応して石灰化し、石のように硬くなって歯の表面にくっついたものである。歯石は死んだ菌の集まりであり、口腔内バイオフィルムのようにそのものが歯周病を引き起こす原因にはならない、歯石の表面はデコボコしているので口腔内バイオフィルムが付着しやすい状態となる。そのため歯茎の炎症をさらに招く結果となる。 Tartar is a plaque that adheres to the teeth and reacts with calcium and phosphoric acid contained in saliva to calcify, becoming hard like stones and sticking to the surface of the teeth. Tartar is a collection of dead bacteria and does not itself cause periodontal disease like the oral biofilm. The surface of the tartar is uneven, so the oral biofilm tends to adhere. Therefore, it results in further inflammation of the gums.
 口腔内で繁殖する菌によって形成されたバイオフィルムは、口臭(文献5. 渋谷耕司, 生理的口臭の成分と由来に関する研究 口腔衛生会誌 J.Dent.Hlth,51 :778 ?792 ,2001、文献6. J.Washio, et al. (2005) Hydrogen sulfide -producinng bacteria in tongue biofilm and their relationship with oral malodour. J. Med. Microbiol. , 54, 889 -895 .参照)、口腔内フローラのバランス異常、口腔内の不衛生化、歯周病(文献7. 門脇知子ら、歯周病とジンジパイン、日薬理誌(Folia Pharmacol. Jpn.)122、37-44 2003.参照)、さらに歯周病に関連した全身疾患(文献8. 廣畑直子ら、歯周病と全身疾患、日大医誌、73 (5): 211-218 (2014).参照)などの原因になっていることが知られている。口腔内バイオフィルムは1種類の菌から構成されるわけではなく、様々な菌が複合的に繁殖することで形成されている。より具体的には病原性バイオフィルムの成立機序は、三段階に分けられている。(文献9. Masae Kuboniwa, et al., Subgingival biofilm formation. Periodontology, 2000 52, 38-52.2010. 、文献10. Paul E.Kolenbrander, et al., Oral multispecies biofilm development and the key role of cell-cell distance. Nat. Rev. Microbiol. 8, 471-480. 2010. 、文献11. Paul E. Kolenbrander, et al., Communication among Oral Bacteria, MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Sept. 2002, p. 486-505.参照)。 Biofilms formed by bacteria that propagate in the oral cavity are found in halitosis (Reference 5. Koji Shibuya, Study on the components and origin of physiological halitosis, Oral Hygiene Journal, J. Dent. Hlth, 51: 778? 792, 2001, Reference 6). . J. Washio, et al. (2005) Hydrogen sulfide-producinng bacteria in tongue biofilm and their relationship with oral malodour. J. Med. Microbiol., 54, 889-895.), Oral flora imbalance, oral cavity Unsanitary conditions in the mouth, periodontal disease (Refer to 7. Tomoko Kadowaki et al., Periodic disease and gingipine, Nikkei Journal (Folia Pharmacol. Jpn.) 122, 37-44 2003.), and related to periodontal disease. It is known to be the cause of systemic diseases (see 8. Naoko Hirohata et al., Halitosis and systemic diseases, Nihon University Medical Journal, 73 (5): 211-218 (2014).). Oral biofilms are not composed of one type of fungus, but are formed by the complex propagation of various fungi. More specifically, the mechanism of establishment of pathogenic biofilms is divided into three stages. (Reference 9. Masae Kuboniwa, et al., Subgingival biofilm formation. Periodontology, 2000 52, 38-52. 2010., Reference 10. Paul E. Kolenbrander, et al., Oral multispecies biofilm development and the key cell distance. Nat. Rev. Microbiol. 8, 471-480. 2010., Reference 11. Paul E. Kolenbrander, et al., Communication amon Oral Bacteria, MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Sept. .reference).
 図1(文献11.参照)は、口腔内バイオフィルムの形成モデルを示す図である。口腔内バイオフィルムの形成過程は次の通りである。はじめに歯の表面に唾液中のタンパク質が付着し、ペリクルとよばれる被膜を形成する。続いて、ペリクルにS. gordonii、S. mitisなどの初期付着菌が固層表面へ付着しコロニーを形成する。次に仲介菌F. nucleatumが菌叢へ付着、さらにその後、後期付着菌として歯周病の主な原因となる病原菌であるP. gingivalis、T. denticola、P. intermedia、A. actinomycetemcomitansなどが菌叢へ付着という三段階でバイオフィルムは形成されている。 FIG. 1 (see Reference 11.) is a diagram showing a formation model of an intraoral biofilm. The process of forming the intraoral biofilm is as follows. First, proteins in saliva adhere to the surface of teeth and form a film called pellicle. Subsequently, initial adhering bacteria such as S. gordonii and S. mitis adhere to the surface of the solid layer to form colonies on the pellicle. Next, the mediator F. nucleatum adheres to the flora, and then P. gingivalis, T. denticola, P. intermedia, A. actinomycetemcomitans, which are pathogens that are the main cause of periodontal disease as late adherent bacteria, are bacteria. The biofilm is formed in three stages: attachment to the flora.
 このことから、初期付着菌であるS. gordonii、S. mitisや仲介菌F. nucleatumが形成したバイオフィルムの形成を阻害または除去することができれば、後期付着菌も定着することができないと考えられる。その結果として口腔内バイオフィルムによって引き起こされる口腔内フローラのバランス異常、口臭の予防(文献5、文献6.参照)、口腔内の不衛生化、歯周病の予防(文献7.参照)、歯周病に起因する全身疾患(文献8.参照)を予防できると考えられる。
<初期付着菌や仲介菌の特性>
From this, it is considered that if the formation of biofilm formed by the early adherent bacteria S. gordonii, S. mitis and the mediator F. nucleatum can be inhibited or eliminated, the late adherent bacteria cannot be established. .. As a result, imbalance of oral flora caused by oral biofilm, prevention of halitosis (see References 5 and 6), oral unsanitization, prevention of periodontal disease (see Reference 7), teeth It is considered that systemic diseases caused by peri-illness (see Reference 8.) can be prevented.
<Characteristics of initial adhering bacteria and mediators>
 初期付着菌であるグラム陽性菌S. gordonii、グラム陽性菌S. mitisなどや仲介菌であるグラム陰性菌F. nucleatumはバイオフィルムを形成し、さまざまな口腔内のトラブルを発生させることが知られている。例えば、S. gordoniiでは、口腔におけるバイオフィルム形成や、それに続く齲蝕、歯肉炎の発症に関与しているのみならず、感染性心内膜炎の原因菌として歯学・医学領域において注目されている(文献12. 高橋幸裕ら、口腔連鎖球菌のアドヘジン、日本細菌学雑誌、62(2), 283-293, 2013.参照)。 It is known that Gram-positive bacteria S. gordonii, Gram-positive bacteria S. mitis, etc., which are early adherent bacteria, and Gram-negative bacteria F. nucleatum, which are mediators, form biofilms and cause various oral problems. ing. For example, S. gordonii is not only involved in the formation of biofilm in the oral cavity and the subsequent onset of dental caries and gingival inflammation, but is also attracting attention in the fields of dentistry and medicine as the causative agent of infective endocarditis. (Refer to Reference 12. Yukihiro Takahashi et al., Adhesin of Oral Streptococcus pyogenes, Journal of Japanese Bacteriology, 62 (2), 283-293, 2013.).
 S. gordoniiはP. gingivalisが歯垢の構成細菌となる際、接着因子として重要な働きを担っていると言われている。さらには、直接的な歯周組織の破壊および歯周組織中のマクロファージなど免疫細胞を刺激して、炎症性サイトカインなどのメディエーターを産生し、組織に傷害を与えていることや歯周炎関連細胞の病巣への定着、増殖に影響を及ぼすなどの間接的な機構により歯周炎に関与している可能性が示されている(文献13. 田近志保子ら、健康成人および歯周炎患者の口腔レンサ球菌の分布について、岩医大歯誌、21, 66-77, 1996. 参照)。S. mitisでは、菌体外に炎症性サイトカインの産生を誘導する物質を産生し、種々の炎症性疾患の起炎菌としての可能性が示唆されている。 S. gordonii is said to play an important role as an adhesion factor when P. gingivalis becomes a constituent bacterium of dental plaque. Furthermore, it directly destroys periodontal tissue and stimulates immune cells such as macrophages in the periodontal tissue to produce mediators such as inflammatory cytokines, causing damage to the tissue and periodontitis-related cells. It has been shown that it may be involved in periodontitis by indirect mechanisms such as colonization of the lesion and influence of proliferation (Reference 13. Shihoko Tajika et al., Oral cavity of healthy adults and patients with periodontitis. For the distribution of Lenza bulbs, see Iwa Medical University Dental Journal, 21, 66-77, 1996.). S. mitis produces a substance that induces the production of inflammatory cytokines outside the cells, suggesting its potential as a causative agent of various inflammatory diseases.
 F. nucleatumでは口臭の原因である臭気物質であるメチルメルカプタン(CH3SH)の高生産菌として知られており口臭の主な原因を作りだしていること(文献5. 、文献14. 松井美樹ら,歯周炎を有さない若年者の口臭に対する歯肉の状態と歯垢および舌苔中細菌の関与. :岩医大歯誌, 38:93-106, 2014.参照)などが知られている。
<口臭>
In F. nucleatum, it is known as a high-producing bacterium of methyl mercaptan (CH 3 SH), which is an odorous substance that causes halitosis, and it is the main cause of halitosis (Reference 5., Reference 14. Miki Matsui et al.) , The condition of gingiva and the involvement of bacteria in halitosis and tongue moss on halitosis in young people without periodontitis.
<Halitosis>
 口臭の原因である臭気物質は、口腔に存在するタンパク質をもととするアミノ酸を基質として口腔内の細菌が産生する硫化水素(H2S)やメチルメルカプタン(CH3SH)である。不快臭がある呼気および口気には、揮発性硫黄化合物(VSC:Volatile Sulfur Compounds)の内、メチルメルカプタンが常に認知閾値に対して高濃度で存在し、かつ官能評価値(不快度)の高低とよく対応したことから、これが不快臭の主要な成分であることが確認されている。メチルメルカプタンは、歯周病関連菌であるPorphyromonasやFusobacteriumに高い生産能力が認められている(文献5. 、文献6. 参照)。 The odorous substances that cause halitosis are hydrogen sulfide (H 2 S) and methyl mercaptan (CH 3 SH) produced by bacteria in the oral cavity using amino acids based on proteins present in the oral cavity as substrates. Among volatile sulfur compounds (VSC: Volatile Sulfur Compounds), methyl mercaptan is always present at a high concentration relative to the cognitive threshold, and the sensory evaluation value (discomfort) is high or low in exhaled breath and mouth with an unpleasant odor. It has been confirmed that this is the main component of the unpleasant odor. Methyl mercaptan has been found to have high production capacity in periodontal disease-related bacteria Porphyromonas and Fusobacterium (see References 5 and 6).
 F. nucleatumは、線状の長いグラム陰性嫌気性菌で、口腔内バイオフィルムなどでは大きな体積比率で存在している。ヒトの口腔内に常在し、菌の両端が尖って中心部がやや太いことから紡錘菌とも言われる。F. nucleatumは、歯周病原性菌の1つで、口腔内バイオフィルム形成に中心的役割を担っていて、他の細菌と共凝集することにより口腔内バイオフィルムを形成する。(文献9.、文献10.、文献11.参照)。また、糖分解能がなく悪臭(口臭)の原因となる酪酸を産生する。(文献5. 参照)。
<口腔内フローラのバランス異常>
F. nucleatum is a long linear gram-negative anaerobic bacterium that is present in large volume ratios in oral biofilms and the like. It is resident in the human oral cavity and is also called a spindle bacterium because both ends of the bacterium are sharp and the central part is slightly thick. F. nucleatum is one of the periodontopathogenic bacteria that plays a central role in the formation of oral biofilms and forms an oral biofilm by co-aggregating with other bacteria. (See Ref. 9, Ref. 10, and Ref. 11.). In addition, it produces butyric acid, which has no sugar resolution and causes bad odor (halitosis). (See Reference 5.).
<Unbalanced oral flora>
 健康な口腔内では、バイオフィルムの約75%が常在菌(グラム陽性好気性球桿菌)であり、歯周病の病原性はない。一方、成人型歯周炎の歯周ポケットでは、Fusobacterium、Porphyromonas、Treponema、Prevotella、Aggregatibacterなどのグラム陰性菌がバイオフィルム内で増殖し、グラム陰性嫌気性球桿菌が口腔内の約75%を占めるようになり、口腔内フローラのバランスが崩れる。
<カンジダ症>
In a healthy oral cavity, about 75% of biofilms are indigenous bacteria (gram-positive aerobic bacilli) and are not pathogenic for periodontal disease. On the other hand, in the periodontal pocket of adult periodontitis, gram-negative bacteria such as Fusobacterium, Porphyromonas, Treponema, Prevotella, and Aggregatibacter grow in the biofilm, and gram-negative anaerobic bacilli occupy about 75% of the oral cavity. And the balance of the oral flora is lost.
<Candidiasis>
 口の中にカビの仲間の細菌が増え、痛みや違和感、味覚障害などを起こす病気である。特に、免疫の低下している高齢者に起こりやすい。さらに、咽頭・食道のカンジダ症も併発するおそれもある。
<誤嚥性肺炎>
It is a disease that causes pain, discomfort, and dysgeusia due to the increase of fungal bacteria in the mouth. It is especially likely to occur in the elderly with weakened immunity. In addition, candidiasis of the pharynx and esophagus may also occur.
<Aspiration pneumonia>
 口腔内細菌が誤って気管から肺に入り炎症が広がると、肺炎を起こすことがある。食事の際に頻繁にむせたり、以前より時間がかかったり、呼吸が苦しかったりなどの症状から始まる。特に、飲み込む力が衰えている高齢者や、脳血管疾患や筋肉の疾患などで飲み込む力が上手く機能しない患者などは注意が必要である。重度の場合は命に関わることもある。
<感染性心内膜症>
Pneumonia can occur when oral bacteria accidentally enter the lungs through the trachea and spread inflammation. It begins with symptoms such as frequent eating, taking longer than before, and difficulty breathing. Particular attention should be paid to elderly people whose swallowing ability is weakened and patients whose swallowing ability does not function well due to cerebrovascular disease or muscle disease. In severe cases, it can be life-threatening.
<Infective endocarditis>
 口腔内細菌が血液に乗って全身に周り、心臓に感染を起こして心疾患を引き起こす場合がある。また、重篤化により、命に関わることもある。
<その他の口腔内フローラが関与する疾病>
Bacteria in the oral cavity may get on the blood and spread throughout the body, infecting the heart and causing heart disease. In addition, it may be fatal due to seriousness.
<Other diseases involving oral flora>
 例えば、敗血症、心筋炎、動脈硬化、糖尿病、皮膚炎、腎炎、リウマチ性関節炎、骨粗鬆症など口腔内フローラが関与している。
<口腔内の不衛生化>
For example, oral flora such as sepsis, myocarditis, arteriosclerosis, diabetes, dermatitis, nephritis, rheumatoid arthritis, and osteoporosis is involved.
<Unsanitary in the oral cavity>
 F. nucleatumは線状の長いグラム陰性嫌気性菌である。口腔内バイオフィルムの中では、体積的には大きな比率を占める。ヒトの口腔内に常在し、紡錘形を呈している。この菌は、口腔内バイオフィルムの形成の中心菌で、その他の菌とともに凝集することで、口腔内バイオフィルムを形成する。
<歯周病>
F. nucleatum is a long linear gram-negative anaerobic bacterium. It occupies a large volume in the oral biofilm. It is resident in the human oral cavity and has a spindle shape. This bacterium is the central bacterium for the formation of oral biofilm, and forms an oral biofilm by aggregating with other bacteria.
<Periodontal disease>
 歯周病菌であるグラム陰性偏性嫌気性細菌P. gingivalisは歯周炎の発症・進行において重要視されている病原性細菌であり、菌体表面および菌体外に強力なプロテアーゼを産生することで、歯周病に関連する種々の状態を生み出すと考えられている(文献7. 参照)。また、P. gingivalisは口腔内バイオフィルムへ付着することが知られており、歯周病を予防するためには、P. gingivalisが付着する口腔内バイオフィルムのコントロールも重要であると考えられる。 P. gingivalis, a gram-negative obligate anaerobic bacterium that is a periodontal disease bacterium, is a pathogenic bacterium that is regarded as important in the onset and progression of periodontitis, and produces a strong protease on the surface of the bacterium and outside the bacterium. It is thought to produce various conditions related to periodontal disease (see Reference 7.). In addition, P. gingivalis is known to adhere to the oral biofilm, and it is considered important to control the oral biofilm to which P. gingivalis adheres in order to prevent periodontal disease.
 P. gingivalisは内毒素(LPS)、プロテアーゼ、線毛、酪酸などの病原因子を生産し歯肉や歯槽骨の吸収や組織間隙に入りこみ歯周組織破壊に関与し、心血管系疾患などの歯周病に誘発される全身疾患との関連が深いと考えられている。その他にも、歯周病の発症・進行において重要視されている病原性細菌が存在しており、侵襲性歯周炎への密接な関連があるといわれているA. actinomycetemcomitansは、菌体外に小胞をもち、内毒素やロイコトキシンなどの毒素が存在し、細胞のアポトーシスを誘導し、P. intermediは侵襲性歯周炎に関与している思春期性歯肉炎や妊娠性歯肉炎に関与していると指摘されている。
<P. gingivalisなどが炎症を起こすメカニズム>
P. gingivalis produces pathogenic factors such as internal toxins (LPS), proteases, fibrous hair, and butyric acid, which penetrates into the resorption of gingiva and alveolar bone and enters the tissue gap, and is involved in periodontal tissue destruction. It is thought to be closely related to disease-induced systemic diseases. In addition, there are pathogenic bacteria that are regarded as important in the onset and progression of periodontal disease, and A. actinomycetemcomitans, which is said to be closely related to invasive periodontitis, is extrabacterial. It has vesicles, and toxins such as internal toxins and leukotoxins are present, which induces cell apoptosis, and P. intermedi is associated with invasive periodontitis for adolescent gingitis and gestational gingitis. It has been pointed out that they are involved.
<Mechanism of inflammation caused by P. gingivalis>
 バイオフィルムを形成している菌が生産するLPSやジンジパインやロイコトキシンなどの毒素が歯周組織局所の炎症反応を引き起こしている。さらにIL-1β、TNF-αなどの各種サイトカインや酵素が歯周組織を破壊する。慢性的に歯周組織を刺激し続けられると、宿主細胞は歯周組織において持続的な、または過剰な免疫反応を起こし歯周組織の破壊が繰り返される。
<歯周病の先に>
Toxins such as LPS, gingipain, and leukotoxin produced by the bacteria forming the biofilm cause an inflammatory reaction locally in the periodontal tissue. Furthermore, various cytokines and enzymes such as IL-1β and TNF-α destroy periodontal tissue. If the periodontal tissue is continuously stimulated chronically, the host cells cause a continuous or excessive immune reaction in the periodontal tissue, and the periodontal tissue is repeatedly destroyed.
<Beyond periodontal disease>
 近年では、誤嚥性肺炎や糖尿病、動脈硬化、妊娠合併症などの全身疾患との関連にも注目されている。これは、歯周病が、口腔内局所の炎症にとどまらず、菌そのものや免疫反応により産生される炎症性サイトカイン(IL-1β, 6, 8, TNF-α など)をはじめとする炎症因子が血流を介し全身に影響を及ぼすことで、しばしば全身状態の悪化を引き起こす。そのため、歯周病原菌やその免疫反応を介した全身への炎症の波及は、歯周病と全身疾患との関わりを関連づけるものとして注目されてきている(文献8. 参照)。
<口腔内バイオフィルム形成について補足>
In recent years, attention has also been paid to the relationship with systemic diseases such as aspiration pneumonia, diabetes, arteriosclerosis, and pregnancy complications. This is because periodontal disease is not limited to local inflammation in the oral cavity, but is caused by inflammatory factors such as inflammatory cytokines (IL-1β, 6, 8, TNF-α, etc.) produced by the bacteria themselves and immune reactions. By affecting the whole body through the bloodstream, it often causes deterioration of the general condition. Therefore, the spread of inflammation to the whole body through periodontal pathogens and their immune reactions has been attracting attention as a link between periodontal disease and systemic disease (see Reference 8.).
<Supplementary information on oral biofilm formation>
 歯面には、タンパク質や有機物が結合したぺリクルと言われるものが形成される。次に、ペリクルのタンパク質のレセプターに付着してコロニーをつくり始めるのが初期定着菌群(Early Colonizers)と呼ばれる特定の口腔の常在菌である。具体的には、S. mitis、S. gordoniiなどが口腔常在菌の中の初期定着菌群として定着する。初期定着菌群によるコロニーが歯面に形成されるとペリクルは隠れて見えなくなってくる。次に、初期定着菌群の細菌表面の表層タンパク質をレセプターとして、それに対するアドヘジンを持つ細菌群が増殖する。すると次から次にレセプターとアドヘジンの関係で理路整然と細菌が定着・増殖していく。このようにして、後期定着菌群によるコロニーが出来上がる。この時、口腔では紡錘菌F. nucleatumがこの中心的な役割果たしている。 On the tooth surface, what is called a pericle to which proteins and organic substances are bound is formed. Next, it is a specific oral indigenous bacterium called an early colonizers that attaches to the protein receptor of the pellicle and begins to form a colony. Specifically, S. mitis, S. gordonii, etc. are established as an early colonization group among indigenous oral bacteria. When colonies formed by the early colonization bacteria are formed on the tooth surface, the pellicle is hidden and disappears. Next, the bacterial group having adhesin against the surface protein on the bacterial surface of the early colonization group grows as a receptor. Then, the bacteria settle and proliferate in a coherent manner due to the relationship between the receptor and adhesin. In this way, colonies of late colonization bacteria are completed. At this time, the spindle fungus F. nucleatum plays a central role in the oral cavity.
 これらの後期定着菌群は初期定着菌群の代謝産物を利用してさらに代謝を続けると同時に、自分自身の代謝産物を産生し、この代謝産物を他の細菌が順に利用する関係となる。A. actinomycetemcomitans、P. intermedia、P. gingivalis、T. denticolaは代表的な歯周病菌であり、歯周病菌は歯を磨かないと増殖して出現する細菌であることがわかる。
<実施形態1 試験>
<試験方法>
<微生物の前培養>
These late colonization groups continue to metabolize by utilizing the metabolites of the early colonization bacteria group, and at the same time, they produce their own metabolites, and other bacteria use these metabolites in order. It can be seen that A. actinomycetemcomitans, P. intermedia, P. gingivalis, and T. denticola are typical periodontal disease bacteria, and periodontal disease bacteria are bacteria that multiply and appear unless the teeth are brushed.
<Embodiment 1 test>
<Test method>
<Preculture of microorganisms>
 ブレインハートインフュージョンブイヨン培地(日水製薬株式会社)にてS. gordonii(初期付着菌)、S. mitis(初期付着菌)、F. nucleatum subsp. nucleatum (JCM No. 8532)をそれぞれ6から7日間、37℃、嫌気条件下(アネロパック・ケンキ、三菱ガス化学株式会社)で前培養した。
<バイオフィルム形成阻害試験>
Brainheart infusion bouillon medium (Nissui Pharmaceutical Co., Ltd.) with S. gordonii (initial adherent bacteria), S. mitis (initial adherent bacteria), F. nucleatum subsp. Nucleatum (JCM No. 8532) 6 to 7 respectively. Precultured for days at 37 ° C. under anaerobic conditions (Aneropack Kenki, Mitsubishi Gas Chemicals Co., Ltd.).
<Biofilm formation inhibition test>
 図2は、バイオフィルム形成阻害試験の方法を示す概念図である。まず、クリーンベンチ内で96ウェルプレートをアカシア樹皮抽出物サンプルで5分間浸漬した後、アカシア樹皮抽出物サンプルを除去し60分風乾した。前培養したS. gordonii(初期付着菌)、S. mitis(初期付着菌)、F. nucleatum subsp. nucleatum (JCM No. 8532)を培地に対して1%ずつ植菌した菌液をアカシア樹皮抽出物サンプルでコーティングした96ウェルプレートへ100 μLずつ添加した。その後、2日間、37℃、嫌気条件下で静置培養し、バイオフィルムを形成させた。2日後、上清を除去し、バイオフィルムをピペッティングにより剥離し、遊離した菌の濁度を570nmの波長にて測定した。ポジティブコントロールとして、ベルベリン、塩化セチルピリジニウム(CPC)および洗口液GUMナイトケア(ノンアルコールタイプ)(サンスター株式会社)を使用した。
<バイオフィルム除去試験>
FIG. 2 is a conceptual diagram showing a method of a biofilm formation inhibition test. First, a 96-well plate was immersed in an acacia bark extract sample for 5 minutes in a clean bench, then the acacia bark extract sample was removed and air-dried for 60 minutes. Acacia bark extraction is performed by inoculating pre-cultured S. gordonii (initial adherent bacteria), S. mitis (initial adherent bacteria), and F. nucleatum subsp. Nucleatum (JCM No. 8532) in 1% each of the medium. 100 μL was added to each of the 96-well plates coated with the product sample. Then, it was statically cultured for 2 days at 37 ° C. under anaerobic conditions to form a biofilm. Two days later, the supernatant was removed, the biofilm was stripped by pipetting, and the turbidity of the liberated bacteria was measured at a wavelength of 570 nm. Berberine, cetylpyridinium chloride (CPC) and mouthwash GUM Night Care (non-alcoholic type) (Sunstar Co., Ltd.) were used as positive controls.
<Biofilm removal test>
 図3は、バイオフィルム除去試験の方法を示す概念図である。まず、前培養したS. gordoni(初期付着菌)、S. mitis(初期付着菌)、F. nucleatum subsp. nucleatum (JCM No. 8532)を培地に対して1%ずつ植菌した菌液を96ウェルプレートへ100 μLずつ添加した。その後、6日間、37℃、嫌気条件下で静置培養し、バイオフィルムを形成させた。上清を除去後、96ウェルプレートに形成したバイオフィルムをアカシア樹皮抽出物サンプルに3分間浸漬した。遊離した菌の濁度を570nmの波長にて測定した。ポジティブコントロールとして、ベルベリン、塩化セチルピリジニウム(CPC)および洗口液GUMナイトケア(ノンアルコールタイプ)(サンスター株式会社)を使用した。
<試験結果 バイオフィルム形成阻害>
FIG. 3 is a conceptual diagram showing a method of a biofilm removal test. First, 96 inoculated 1% each of pre-cultured S. gordoni (initial adherent bacteria), S. mitis (initial adherent bacteria), and F. nucleatum subsp. Nucleatum (JCM No. 8532) into the medium. 100 μL each was added to the well plate. Then, it was statically cultured for 6 days at 37 ° C. under anaerobic conditions to form a biofilm. After removing the supernatant, the biofilm formed on a 96-well plate was immersed in an acacia bark extract sample for 3 minutes. The turbidity of the liberated bacteria was measured at a wavelength of 570 nm. Berberine, cetylpyridinium chloride (CPC) and mouthwash GUM Night Care (non-alcoholic type) (Sunstar Co., Ltd.) were used as positive controls.
<Test results Inhibition of biofilm formation>
 図4は、バイオフィルム形成阻害試験の結果を示す図であり、アカシア樹皮抽出物サンプルを前処理した96ウェルプレートに形成されたバイオフィルムの割合を示したものである。図示するように、コントロールと比較して、アカシア樹皮抽出物サンプルで前処理した試験区では、バイオフィルムの形成率低下が確認できた。特に、アカシア樹皮抽出物サンプル3mg/mLの濃度処理区では、コントロール(水)と比較して有意にバイオフィルムの形成を阻害することが認められた。
<試験結果 バイオフィルム除去>
FIG. 4 shows the results of the biofilm formation inhibition test, showing the proportion of biofilm formed on 96-well plates pretreated with acacia bark extract samples. As shown in the figure, a decrease in the biofilm formation rate was confirmed in the test plots pretreated with the acacia bark extract sample as compared with the control. In particular, in the acacia bark extract sample 3 mg / mL concentration treatment group, it was found that the formation of biofilm was significantly inhibited as compared with the control (water).
<Test result Biofilm removal>
 図5は、バイオフィルム除去試験の結果を示す図であり、96ウェルプレートに形成されたバイオフィルムがアカシア樹皮抽出物サンプルの処理により遊離した菌の濁度を示したものである。その結果、本検討で試験した全てのアカシア樹皮抽出物サンプル処理区で、コントロール(水)と比較して有意にバイオフィルムから菌が遊離していることが確認できた。また、ポジティブコントロールと比較した場合でも、アカシア樹皮抽出物サンプルのバイオフィルム除去能は高いことが示唆された。
<飲食料>
FIG. 5 is a diagram showing the results of the biofilm removal test, showing the turbidity of the bacteria released by the biofilm formed on the 96-well plate by the treatment of the acacia bark extract sample. As a result, it was confirmed that the bacteria were significantly released from the biofilm in all the acacia bark extract sample treatment groups tested in this study as compared with the control (water). It was also suggested that the biofilm removing ability of the acacia bark extract sample was high even when compared with the positive control.
<Food and drink>
 本実施形態の口腔内フローラ改善・維持剤の形態は、様々であり、固形、粒形、液体、ゲル状、粉体、ペーストなどの形態で提供することができる。さらに既知の方法を用いることにより、当該口腔内フローラ改善・維持剤を含有する飲食料、口腔洗浄剤、歯磨剤などとして提供することが可能である。 There are various forms of the oral flora improving / maintaining agent of the present embodiment, and they can be provided in the form of solid, granular, liquid, gel, powder, paste and the like. Further, by using a known method, it can be provided as a food or drink, an oral cleanser, a dentifrice or the like containing the oral flora improving / maintaining agent.
 例えば、飲食料とする場合には、茶、清涼飲料水、乳酸菌飲料、野菜飲料、スポーツ飲料、コーヒー、ココア、酒などの各種飲料や、缶詰、冷凍食品、レトルト食品、即席スープ(味噌汁)、たれ・ドレッシング・ソースなどの調味液、麺、乳製品、ジャム、飴、キャラメル、ガム、チョコレート、ビスケット、ケーキ、和菓子、アイスクリーム、シリアル、魚肉加工品などの種々の飲食料に口腔内フローラ改善・維持剤を適宜含有させることで、口腔内フローラ改善・維持用の飲食料として提供することができる。
<口腔洗浄剤>
For example, when it comes to food and drink, various beverages such as tea, soft drinks, lactic acid bacteria beverages, vegetable beverages, sports beverages, coffee, cocoa, and liquor, canned foods, frozen foods, retort foods, and instant soups (miso juice), Improved oral flora for various foods and drinks such as seasonings such as sauce, dressing and sauce, noodles, dairy products, jams, candy, caramel, gum, chocolate, biscuits, cakes, Japanese sweets, ice cream, cereals, processed fish meat products, etc. -By appropriately containing a maintenance agent, it can be provided as a food and drink for improving and maintaining the oral flora.
<Oral cleanser>
 また、口腔洗浄剤(洗口剤、口内洗浄剤、デンタルリンス、マウスウォッシュなどとも呼ばれる)とする場合には、グルコン酸クロルヘキシジン、塩化セチルピリジウム、塩化ベンゼトニウム、ポピドンヨード、エッセンシャルオイル、トリクロサン、エタノール及び適量の水とともに口腔内フローラ改善・維持剤を適宜含有させることで、口腔内フローラ改善・維持用の口腔洗浄剤として提供することができる。
<歯磨剤>
When used as an oral cleansing agent (also called mouthwash, mouthwash, dental rinse, mouthwash, etc.), chlorhexidine gluconate, cetylpyridium chloride, benzethonium chloride, popidone iodine, essential oil, triclosan, ethanol and an appropriate amount By appropriately containing the oral flora improving / maintaining agent together with the water, it can be provided as an oral cleaning agent for improving / maintaining the oral flora.
<Toothpaste>
 また、歯磨剤とする場合には、炭酸カルシウム、水酸アパタイト、リン酸水素カルシウム、水酸化アルミニウム、アルミナ、シリカ、ラウロイルサルコシンソーダ、ラウリル硫酸ナトリウム、ショ糖脂肪酸エステル、石ケン素地、アルキルグリコシド、ソルビトール、グリセリン、プロピレングリコール、アルギン酸ナトリウム、カルボキシメチルセルロース、フッ化ナトリウム、デキストラナーゼ、クロルヘキシジン、塩化ナトリウムなどとともに口腔内フローラ改善・維持剤を適宜含有させることで、口腔内フローラ改善・維持用の歯磨剤として提供することができる。 When used as a dentifrice, calcium carbonate, hydroxyapatite, calcium hydrogenphosphate, aluminum hydroxide, alumina, silica, lauroyl sarcosin soda, sodium lauryl sulfate, sucrose fatty acid ester, dextranase base, alkyl glycoside, Toothpaste for improving and maintaining oral flora by appropriately containing an oral flora improving / maintaining agent together with sorbitol, glycerin, propylene glycol, sodium alginate, carboxymethyl cellulose, sodium fluoride, dextranase, chlorhexidine, sodium chloride, etc. It can be provided as an agent.

Claims (16)

  1.  アカシアの樹皮抽出物を有効成分とする口腔内フローラ改善・維持剤。 An oral flora improving / maintaining agent containing acacia bark extract as an active ingredient.
  2.  アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルム(プラーク、歯垢)からの離脱を促進する請求項1に記載の口腔内フローラ改善・維持剤。 The oral flora improving / maintaining agent according to claim 1, which promotes the withdrawal of gram-negative bacteria and / and gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm (plaque, plaque).
  3.  アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルム(プラーク、歯垢)の形成を抑制する請求項1に記載の口腔内フローラ改善・維持剤。 The oral flora improving / maintaining agent according to claim 1, which suppresses the formation of oral biofilms (plaque, plaque) of gram-negative bacteria and / and gram-positive bacteria containing acacia bark extract as an active ingredient.
  4.  前記グラム陰性菌又は/及びグラム陽性菌は、Streptococcus gordonii、Streptococcus mitis、Fusobacterium nucleatum、Porphyromonas gingivalis、Treponema spp、Tannerella forsythiaのうちの少なくとも二以上を含む請求項2又は請求項3に記載の口腔内フローラ改善・維持剤。 The oral flora according to claim 2 or 3, wherein the gram-negative bacterium and / and the gram-positive bacterium includes at least two or more of Streptococcus gordonii, Streptococcus mitis, Fusobacterium nucleatum, Porphyromonas gingivalis, Treponema spp, and Tannerella forsythia. Improvement / maintenance agent.
  5.  請求項1から請求項4のいずれか一に記載の口腔内フローラ改善・維持剤を含有した飲食料。 A food or drink containing the oral flora improving / maintaining agent according to any one of claims 1 to 4.
  6.  請求項1から請求項4のいずれか一に記載の口腔内フローラ改善・維持剤を含有した口腔洗浄剤。 An oral cleansing agent containing the oral flora improving / maintaining agent according to any one of claims 1 to 4.
  7.  請求項1から請求項4のいずれか一に記載の口腔内フローラ改善・維持剤を含有した歯磨剤。 A dentifrice containing the oral flora improving / maintaining agent according to any one of claims 1 to 4.
  8.  アカシアの樹皮抽出物を有効成分とする歯石形成予防剤。 A tartar formation preventive agent containing acacia bark extract as an active ingredient.
  9.  アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムからの離脱を促進する請求項8に記載の歯石形成予防剤。 The tartar formation preventive agent according to claim 8, which promotes the withdrawal of gram-negative bacteria and / and gram-positive bacteria containing acacia bark extract as an active ingredient from the oral biofilm.
  10.  アカシアの樹皮抽出物を有効成分とするグラム陰性菌又は/及びグラム陽性菌の口腔内バイオフィルムの形成を抑制する請求項8に記載の歯石形成予防剤。 The tartar formation preventive agent according to claim 8, which suppresses the formation of an oral biofilm of Gram-negative bacteria and / and Gram-positive bacteria containing acacia bark extract as an active ingredient.
  11.  前記グラム陰性菌又は/及びグラム陽性菌は、Streptococcus gordonii、Streptococcus mitis、Fusobacterium nucleatum、Porphyromonas gingivalis、Treponema spp、Tannerella forsythiaのうちの少なくとも二以上を含む請求項9又は請求項10に記載の歯石形成予防剤。 The prevention of dentin formation according to claim 9 or claim 10, wherein the gram-negative bacterium and / and the gram-positive bacterium includes at least two or more of Streptococcus gordonii, Streptococcus mitis, Fusobacterium nucleatum, Porphyromonas gingivalis, Treponema spp, and Tannerella forsythia. Agent.
  12.  請求項8から請求項11のいずれか一に記載の歯石形成予防剤を含有した飲食料。 A food or drink containing the tartar formation preventive agent according to any one of claims 8 to 11.
  13.  請求項8から請求項11のいずれか一に記載の歯石形成予防剤を含有した口腔洗浄剤。 An oral cleanser containing the tartar formation preventive agent according to any one of claims 8 to 11.
  14.  請求項8から請求項11のいずれか一に記載の歯石形成予防剤を含有した歯磨剤。 A dentifrice containing the tartar formation preventive agent according to any one of claims 8 to 11.
  15.  請求項8から請求項11のいずれか一に記載の歯石形成予防剤を用いて歯石形成予防する歯石形成予防方法。 A method for preventing tartar formation using the tartar formation preventive agent according to any one of claims 8 to 11.
  16.  請求項1から請求項4のいずれか一に記載の口腔内フローラ改善・維持剤を用いて口腔内フローラを改善・維持する口腔内フローラ改善・維持方法。 An oral flora improvement / maintenance method for improving / maintaining an oral flora using the oral flora improving / maintaining agent according to any one of claims 1 to 4.
PCT/JP2021/031820 2020-09-10 2021-08-31 Agent for improving and maintaining oral flora, and agent for removing dental plaque/teeth plaque and preventing tartar formation WO2022054629A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020151948A JP7448122B2 (en) 2020-09-10 2020-09-10 Oral flora improvement and maintenance agent, plaque/plaque removal and tartar formation prevention agent
JP2020-151948 2020-09-10

Publications (1)

Publication Number Publication Date
WO2022054629A1 true WO2022054629A1 (en) 2022-03-17

Family

ID=80631725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/031820 WO2022054629A1 (en) 2020-09-10 2021-08-31 Agent for improving and maintaining oral flora, and agent for removing dental plaque/teeth plaque and preventing tartar formation

Country Status (2)

Country Link
JP (1) JP7448122B2 (en)
WO (1) WO2022054629A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07242555A (en) * 1994-03-08 1995-09-19 Suntory Ltd Glucosyl transferase-inhibiting agent and dental caries-resistant agent and dental caries-resistant food containing the same as active ingredient
US20070258913A1 (en) * 2004-09-17 2007-11-08 Bart Rossel Composition for Inhibiting or Preventing the Formation of a Biofilm
JP2008517069A (en) * 2004-10-19 2008-05-22 ユニゲン・ファーマシューティカルス・インコーポレーテッド Formulations of dual eicosanoid / cytokine inhibitors for use in the prevention or treatment of oral diseases and conditions
US20090185987A1 (en) * 2008-01-21 2009-07-23 Himalaya Global Holdings Ltd. Herbal dental care composition, method of manufacturing the same and use thereof
JP2009203209A (en) * 2008-02-29 2009-09-10 Mimozax Co Ltd Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia
JP2010105923A (en) * 2008-10-28 2010-05-13 Mimozax Co Ltd PPARdelta EXPRESSION PROMOTER CONTAINING MATERIAL ORIGINATED FROM BARK OF GENUS ACACIA
JP2011051992A (en) * 2010-10-05 2011-03-17 Wood One:Kk Active oxygen scavenger
WO2019026088A1 (en) * 2017-08-01 2019-02-07 Muniyal Ayurvedic Research Centre Oral health care formulation and method of preparation thereof
JP2019195309A (en) * 2018-05-11 2019-11-14 株式会社アカシアの樹 Genus acacia bark-derived substance-containing skin moisturizing composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5398101B2 (en) 2004-01-21 2014-01-29 株式会社東洋新薬 Absorption enhancer of bark extract component containing sphingolipid as active ingredient

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07242555A (en) * 1994-03-08 1995-09-19 Suntory Ltd Glucosyl transferase-inhibiting agent and dental caries-resistant agent and dental caries-resistant food containing the same as active ingredient
US20070258913A1 (en) * 2004-09-17 2007-11-08 Bart Rossel Composition for Inhibiting or Preventing the Formation of a Biofilm
JP2008517069A (en) * 2004-10-19 2008-05-22 ユニゲン・ファーマシューティカルス・インコーポレーテッド Formulations of dual eicosanoid / cytokine inhibitors for use in the prevention or treatment of oral diseases and conditions
US20090185987A1 (en) * 2008-01-21 2009-07-23 Himalaya Global Holdings Ltd. Herbal dental care composition, method of manufacturing the same and use thereof
JP2009203209A (en) * 2008-02-29 2009-09-10 Mimozax Co Ltd Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia
JP2010105923A (en) * 2008-10-28 2010-05-13 Mimozax Co Ltd PPARdelta EXPRESSION PROMOTER CONTAINING MATERIAL ORIGINATED FROM BARK OF GENUS ACACIA
JP2011051992A (en) * 2010-10-05 2011-03-17 Wood One:Kk Active oxygen scavenger
WO2019026088A1 (en) * 2017-08-01 2019-02-07 Muniyal Ayurvedic Research Centre Oral health care formulation and method of preparation thereof
JP2019195309A (en) * 2018-05-11 2019-11-14 株式会社アカシアの樹 Genus acacia bark-derived substance-containing skin moisturizing composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAKSHMI T., DHINAHAR S.: "ANTIBACTERIAL EFFECTIVENESS OF ETHANOLIC EXTRACT OF ACACIA CATECHU BARK AND AZADIRACHTA INDICA LEAF AGAINST STREPTOCOCCUS MUTANS –A COMPARATIVE IN VITRO STUDY ", PHARMA RESEARCH, GHAZIABAD : ANUJ MITTAL, INDIA, vol. 6, no. 2, 1 January 2012 (2012-01-01), India , pages 19 - 23, XP055909912, ISSN: 0975-8216 *

Also Published As

Publication number Publication date
JP7448122B2 (en) 2024-03-12
JP2022046082A (en) 2022-03-23

Similar Documents

Publication Publication Date Title
US6872565B2 (en) Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
JP2016513631A (en) Lactobacillus plantarum NCC2936 preparation and oral health
JP2022162034A (en) Composition for preventing or treating oral disease
EP2146683B1 (en) Use of an aqueous grape seed extract combined with at least one fluorine salt to combat the formation or accumulation of dental biofilm and compositions comprising said combination
WO2022054629A1 (en) Agent for improving and maintaining oral flora, and agent for removing dental plaque/teeth plaque and preventing tartar formation
KR20190041799A (en) Composition for prevention or treatment of oral disease comprising Alkannin
JP2006328052A (en) Composition for disinfecting porphyromonas gingivalis
KR102632524B1 (en) Composition for prevention or treatment periodontal diseases comprising Bacillus velezensis, culture media or culture supernatant thereof as active ingredient
JP7321632B2 (en) Composition for prevention or treatment of oral disease
EP4212612A1 (en) Novel bacillus velezensis strains and uses thereof
US20230381093A1 (en) Bacillus subtilis strain and use thereof
Carlson et al. Olive Oil, Oil Pulling and Dental Health
KR102575768B1 (en) Natural Edible Film Compositions for Preventing or Improving Oral Diseases and Uses Thereof
JP6918529B2 (en) Oral composition
KR20190041801A (en) Composition for prevention or treatment of oral disease comprising Ginkgolide C
KR20180046247A (en) Composition for prevention or treatment of oral disease comprising Verbascoside
KR20180046244A (en) Composition for prevention or treatment of oral disease comprising Cordycepin
KR20180055519A (en) Composition for prevention or treatment of oral disease comprising salvianolic acid A
KR20180046250A (en) Composition for prevention or treatment of oral disease comprising Astilbin
KR20180047705A (en) Composition for prevention or treatment of oral disease comprising Forsythiae Fructus extract
KR20230046727A (en) Composition for preventing biofilm formation comprising zinc salt
KR20230040578A (en) Composition for Inhibiting Biofilm Formation and for Preventing or Treating Dental Disease
KR20180046249A (en) Composition for prevention or treatment of oral disease comprising lithospermic acid
KR20180046246A (en) Composition for prevention or treatment of oral disease comprising Shikonin
KR20180064162A (en) Composition for prevention or treatment of oral disease comprising dihydrotanshinone Ⅰ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21866588

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21866588

Country of ref document: EP

Kind code of ref document: A1